201 related articles for article (PubMed ID: 16409887)
1. Insulin therapy, glycemic control, and cardiovascular risk factors in young Latin Americans with type 2 diabetes mellitus.
Avilés-Santa L; Salinas K; Adams-Huet B; Raskin P
J Investig Med; 2006 Jan; 54(1):20-31. PubMed ID: 16409887
[TBL] [Abstract][Full Text] [Related]
2. Effects of multiple daily insulin injections on peripheral glucose disposal in Latin Americans with type 2 diabetes mellitus.
Avilés-Santa L; Salinas K; Adams-Huet B; Raskin P
J Investig Med; 2007 Jan; 55(1):11-7. PubMed ID: 17441407
[TBL] [Abstract][Full Text] [Related]
3. Anthropometric features and cardiovascular risk in young Latin Americans with type 2 diabetes mellitus.
Avilés-Santa L; Salinas K; Adams-Huet B; Raskin P
J Diabetes Complications; 2006; 20(2):69-74. PubMed ID: 16504834
[TBL] [Abstract][Full Text] [Related]
4. The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes.
Tong PC; Lee ZS; Sea MM; Chow CC; Ko GT; Chan WB; So WY; Ma RC; Ozaki R; Woo J; Cockram CS; Chan JC
Arch Intern Med; 2002 Nov; 162(21):2428-35. PubMed ID: 12437401
[TBL] [Abstract][Full Text] [Related]
5. Adiponectin and E-selectin concentrations in relation to inflammation in obese type 2 diabetic patients with coronary heart disease(s).
El-Mesallamy HO; Hamdy NM; Salman TM; Mahmoud S
Minerva Endocrinol; 2011 Sep; 36(3):163-70. PubMed ID: 22019747
[TBL] [Abstract][Full Text] [Related]
6. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
Mosenzon O; Raz I; Scirica BM; Hirshberg B; Stahre CI; Steg PG; Davidson J; Ohman P; Price DL; Frederich B; Udell JA; Braunwald E; Bhatt DL
Diabetes Metab Res Rev; 2013 Jul; 29(5):417-26. PubMed ID: 23564755
[TBL] [Abstract][Full Text] [Related]
7. Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting: effects of 2 years of gliclazide treatment--the Diadem Study.
Cathelineau G; de Champvallins M; Bouallouche A; Lesobre B
Metabolism; 1997 Dec; 46(12 Suppl 1):31-4. PubMed ID: 9439556
[TBL] [Abstract][Full Text] [Related]
8. LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial.
Masmiquel L; Leiter LA; Vidal J; Bain S; Petrie J; Franek E; Raz I; Comlekci A; Jacob S; van Gaal L; Baeres FM; Marso SP; Eriksson M;
Cardiovasc Diabetol; 2016 Feb; 15():29. PubMed ID: 26864124
[TBL] [Abstract][Full Text] [Related]
9. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
[TBL] [Abstract][Full Text] [Related]
10. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial.
Schaumberg DA; Glynn RJ; Jenkins AJ; Lyons TJ; Rifai N; Manson JE; Ridker PM; Nathan DM
Circulation; 2005 May; 111(19):2446-53. PubMed ID: 15867184
[TBL] [Abstract][Full Text] [Related]
11. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
Dailey G
Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
[TBL] [Abstract][Full Text] [Related]
12. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
Kadoglou NP; Tsanikidis H; Kapelouzou A; Vrabas I; Vitta I; Karayannacos PE; Liapis CD; Sailer N
Metabolism; 2010 Mar; 59(3):373-9. PubMed ID: 19815243
[TBL] [Abstract][Full Text] [Related]
13. Plasma malondialdehyde levels and risk factors for the development of chronic complications in type 2 diabetic patients on insulin therapy.
Kaefer M; De Carvalho JA; Piva SJ; da Silva DB; Becker AM; Sangoi MB; Almeida TC; Hermes CL; Coelho AC; Tonello R; Moreira AP; Garcia SC; Moretto MB; Moresco RN
Clin Lab; 2012; 58(9-10):973-8. PubMed ID: 23163113
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
Ovalle F
Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
[TBL] [Abstract][Full Text] [Related]
15. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
[TBL] [Abstract][Full Text] [Related]
16. Urinary albumin excretion is independently associated with C-reactive protein levels in overweight and obese nondiabetic premenopausal women.
Pannacciulli N; Cantatore FP; Minenna A; Bellacicco M; Giorgino R; De Pergola G
J Intern Med; 2001 Dec; 250(6):502-7. PubMed ID: 11902818
[TBL] [Abstract][Full Text] [Related]
17. Mediating effects of inflammatory biomarkers on insulin resistance associated with obesity.
Wexler DJ; Hu FB; Manson JE; Rifai N; Meigs JB
Obes Res; 2005 Oct; 13(10):1772-83. PubMed ID: 16286525
[TBL] [Abstract][Full Text] [Related]
18. Serum concentrations of soluble adhesion molecules are related to degree of hyperglycemia and insulin resistance in patients with type 2 diabetes mellitus.
Matsumoto K; Sera Y; Nakamura H; Ueki Y; Miyake S
Diabetes Res Clin Pract; 2002 Feb; 55(2):131-8. PubMed ID: 11796179
[TBL] [Abstract][Full Text] [Related]
19. Metformin added to intensive insulin therapy improves metabolic control in patients with type 1 diabetes and excess body fat.
Zawada A; Naskręt D; Burchardt P; Niedźwiecki P; Piłaciński S; Wierusz-Wysocka B; Grzymisławski M; Zozulińska-Ziółkiewicz D
Pol Arch Intern Med; 2018 May; 128(5):294-300. PubMed ID: 29870029
[TBL] [Abstract][Full Text] [Related]
20. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
Avilés-Santa L; Sinding J; Raskin P
Ann Intern Med; 1999 Aug; 131(3):182-8. PubMed ID: 10428734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
